Alivus Life Sciences is trading -9.05% lower at Rs 1,094.00 as compared to its last closing price. Alivus Life Sciences has been trading in the price range of 1,195.80 & 1,070.00. Alivus Life Sciences has given 24.52% in this year & 6.02% in the last 5 days. Alivus Life Sciences has TTM P/E ratio 27.31 as compared to the sector P/E of 28.63.There are 5 analysts who have initiated coverage on Alivus Life Sciences. There are 3 analysts who have given it a strong buy rating & 2 analysts have given it a buy rating. 0.00 analysts have given the stock a sell rating.The company posted a net profit of 136.96 Crores in its last quarter.Listed peers of Alivus Life Sciences include Caplin Point Laboratories (-4.36%), Jubilant Pharmova (-0.61%), Alivus Life Sciences (-9.05%).The Mutual Fund holding in Alivus Life Sciences was at 3.23% in 31 Dec 2024. The MF holding has increased from the last quarter. The FII holding in Alivus Life Sciences was at 6.74% in 31 Dec 2024. The FII holding has decreased from the last quarter.
Updated on Feb 12, 2025, 01:39 AM UTC
|
|
|
|
Names | Technical rating | Price | %Change | Market Cap | P/E | P/B | Dividend Yield | Debt to Equity |
---|---|---|---|---|---|---|---|---|
Caplin Point Laboratories | Moderately Bearish | 2,030.30 | -4.36 | 15,439.88 | 36.97 | 7.27 | 0.23 | 0.04 |
Jubilant Pharmova | Neutral | 993.60 | -0.61 | 15,754.85 | 106.54 | 2.91 | 0.50 | 61.92 |
Alivus Life Sciences | Neutral | 1,094.00 | -9.05 | 13,405.10 | 31.87 | 6.43 | 1.84 | 0.63 |
Granules India | Moderately Bearish | 551.30 | -3.14 | 13,361.47 | 34.71 | 4.38 | 0.26 | 4.72 |
Sanofi India | Bearish | 5,352.00 | -1.34 | 12,325.20 | 21.29 | 12.41 | 3.05 | 1.37 |
Meeting Date | Purpose |
---|---|
2025-01-23 | Quarterly Results |
2024-10-24 | Quarterly Results |
2024-07-25 | Quarterly Results |
2024-04-25 | Audited Results |
2024-01-23 | Quarterly Results |
Alivus Life Sciences is trading at 1094.00 as on Tue Feb 11 2025 09:59:05. This is -9.05% lower as compared to its previous closing price of 1202.85.
The market capitalization of Alivus Life Sciences is 13405.10 Cr as on Tue Feb 11 2025 09:59:05.
The average broker rating on Alivus Life Sciences is Strong Buy. The breakup of analyst rating is given below -
The 52 wk high for Alivus Life Sciences is 1335.00 whereas the 52 wk low is 666.05
Alivus Life Sciences can be analyzed on the following key metrics -
Alivus Life Sciences reported a net profit of 470.89 Cr in 2024.
The Mutual Fund Shareholding was 3.23% at the end of 31 Dec 2024.